Lunatus partners with NantHealth to bring GPS Cancer™ to oncologists and patients in the Middle East

December 6th, 2016

In December 2016, Lunatus entered into an exclusive reseller agreement with NantHealth, a leading next-generation, evidence-based, personalized healthcare company, for GPS Cancer Advanced Molecular Analysis.

The molecular tests will help guide the decisions made by oncologists in the Middle East regarding a patient’s treatment strategy, including choice of standard chemotherapy. Oncologists in the United Arab Emirates, Saudi Arabia, Kuwait, Oman, Bahrain, Qatar, and Lebanon are empowered to make more informed clinical decisions to personalize treatment and care for their patients.

This partnership builds on the international expansion of GPS Cancer, which was recently made available in Italy.

Link to full article:

← Previous Post Next Post →